Cosmetic pharmacology

Cosmetic psychopharmacology, a term coined in 1990 by the psychiatrist Peter D. Kramer and popularized in his 1993 book Listening to Prozac, refers to the use of drugs to move persons from a normal psychological state to another normal state that is more desired or better socially rewarded — e.g., from melancholy toward assertiveness and confidence or from slower to quicker cognition.

The comparison is with surgery in which the same intervention can be therapeutic (as for reparative work on burn victims) or cosmetic (as in rhinoplasty for the enhancement of beauty in conventional terms). In general, cosmetic psychopharmacology refers to the use of psychoactive medications by normal healthy individuals, for the purpose of enhancement rather than treatment of a formal pathology. Kramer reported that with the antidepressant Prozac occasional patients seemed "better than well," and he discussed the ethical dilemmas that might result were similar medications offered to individuals not afflicted with psychiatric disorders. Following these case reports, much controversy arose over the veracity and ethics of the cosmetic use of actual antidepressants and other similar medications. ^[1]

Opponents of cosmetic pharmacology believe that such drug usage is unethical and that the concept of cosmetic pharmacology is a manifestation of naive consumerism. Proponents, such as philosopher Arthur Caplan, state that it is an individual's (rather than government's, or physician's) right to determine whether to use a drug for cosmetic purposes.^[2]

Anjan Chatterjee, a neurologist at the University of Pennsylvania, has argued that western medicine stands on the brink of a neuro-enhancement revolution in which people will be able to improve their memory and attention through pharamacological means. ^[3] Jacob M. Appel, a Brown University ethicist, has raised concerns about the possibility of employers mandating such enhancement for their workers. ^{[4] [5]}

See also

• Performance-enhancing drugs
• Cognitive liberty
• Neuroethics
• Nootropics

References

1. ^ Giannini AJ (2004). "The case for cosmetic psychiatry: Treatment without diagnosis". Psychiatric Times 21 (7): 1. 
2. ^ Caplan, Arthur (September 2003). "Is Better Best? A Noted Ethicist Argues in Favor of Brain Enhancement". Scientific American: 4–5. 
3. ^ Chatterjee, Anjan (September 2004). "Cosmetic neurology: the controversy over enhancing movement, mentation, and mood". Neurology 63 (6): 968–74. PMID 15452285. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15452285. 
4. ^ Appel JM (August 2008). "When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology". J Med Ethics 34 (8): 616–8. doi:10.1136/jme.2007.022723. PMID 18667652. http://jme.bmj.com/cgi/pmidlookup?view=long&pmid=18667652. 
5. ^ Kirby, Jason (October 1, 2008). "Going to Work on Smart Drugs". Maclean's. http://www.macleans.ca/science/health/article.jsp?content=20081001_98115_98115&page=1. 

Scientific articles via PubMed

• Bjorklund P (April 2005). "Can there be a 'cosmetic' psychopharmacology? Prozac unplugged: the search for an ontologically distinct cosmetic psychopharmacology". Nurs Philos 6 (2): 131–43. doi:10.1111/j.1466-769X.2005.00213.x. PMID 15787908. http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1466-7681&date=2005&volume=6&issue=2&spage=131. 
• Psychopharmacology and the human condition
• The Responsible Parent's Guide to Health Mood-boosters for All the Family

External links

• Society for the Advancement of Cosmetic Pharmacotherapy